Could Revolution Medicines Be a Millionaire-Maker Stock?

A return of over 9x in just three years. That's the sizzling trajectory for Revolution Medicines (NASDAQ: RVMD). It's one of the hottest biotech stocks of 2026, with shares soaring more than 130%.

Revolution Medicines' performance is the direct result of buzz about its cancer therapy Rasonque (daraxonrasib). The U.S. Food and Drug Administration (FDA) approved the drug for the treatment of pancreatic cancer in August 2026.

There's no question that investors who jumped aboard the Revolution Medicines train early have made a lot of money so far. But could Revolution Medicines be a millionaire-maker stock going forward?

Image source: Getty Images.

The math to a million

Many stocks could be millionaire-makers if you invest a massive amount upfront. An initial investment of $990,000 wouldn't have to increase much to achieve the goal. However, let's look at what it would take for Revolution Medicines to grow a more realistic investment of $25,000 to $1 million.

Revolution Medicines would need a market cap of roughly $1.6 trillion to make that happen. To put that number into context, the world's largest healthcare company today -- Eli Lilly (NYSE: LLY) -- has a market cap of around $1.2 trillion.

RBC (NYSE: RY) Capital Markets estimates Rasonque's peak annual sales at $11.5 billion. At the average price-to-sales ratio for the biotech industry of 8.4, that level would put Revolution Medicines' market cap near $97 billion.

Revolution's pipeline features other promising candidates. The company is evaluating zoldonrasib in a Phase 3 clinical study for the treatment of first-line metastatic pancreatic cancer. It's also evaluating a combination of the experimental therapy with Merck's (NYSE: MRK) Keytruda and chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC). In addition, Revolution plans to advance elironrasib into late-stage testing in combination with Keytruda and chemo.

The honest answer

If Rasonque fulfills its potential and zoldonrasib and elironrasib win regulatory approvals, Revolution Medicines' market cap could rise significantly above $97 billion. But is the stock likely to reach the $1.6 trillion required to turn an initial $25,000 investment into $1 million? Probably not.

However, a stock doesn't have to be a millionaire-maker to be an impressive moneymaker. Revolution Medicines appears to have what it takes to generate market-beating returns for long-term investors.

Billionaire Stanley Druckenmiller appears to think so. His Duquesne Family Office has placed a big bet on Revolution Medicines and increased its position in the biotech stock by 26.5% in the third quarter of 2026.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Merck. The Motley Fool has a disclosure policy.